ClinicalTrials.gg
CompletedNCT06263881Updated Apr 4, 2025

Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia

A Phase 3 interventional study of Raphamin and Placebo in Community-acquired Pneumonia and Pneumonia, sponsored by Materia Medica Holding. Completed at 38 sites in Russian Federation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by Materia Medica Holding · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
370
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Community-Acquired Pneumonia with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Community-Acquired Pneumonia · Russian Federation.

Enrollment
6th of 12
370 · median 356
Started
2023
the only one that year
Phase 3
7 of 14
none open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Materia Medica Holding

Among the 14 studies in Community-Acquired Pneumonia with a site in Russian Federation, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 7 in phase 3, and was the 14th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 78 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

None of the 14 studies in Community-Acquired Pneumonia with a site in Russian Federation is open now. The open studies under Community-Acquired Pneumonia, anywhere →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Community-Acquired Pneumonia with a site in Russian Federation as a file.
02

Study summary

Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial.

Read the detailed description

Design: a multicenter, double-blind, placebo-controlled, randomized in parallel-group trial.

The study enrolls male and female outpatients aged 18 to 65 years with typical symptoms of community-acquired pneumonia (CAP): axillary body temperature ≥38.00C, acute cough, shortness of breath (dyspnea), chest pain when breathing, fatigue, night sweats. Symptoms are associated with previous upper respiratory tract infection or acute bronchitis. The investigator assesses a prognosis and determines where the patient will receive treatment using the CRB-65 score which includes estimation of Confusion, Respiratory rate, Blood pressure, and Age (≥ 65 years) (min "0", max "4" points; only estimation "0" points is indication for outpatient treatment).

At the first visit (day 1), after signing the patient information sheet and informed consent form for participation in a clinical trial, the investigator collects complaints and medical history, conducts a physical examination and assessment of vital signs, and measures capillary blood oxygen saturation (SpO2), records comorbidities and concomitant therapies, collects blood samples for laboratory tests, and orders a dual-view chest X-ray or chest CT scan. If X-ray/CT shows no changes in the lungs or changes that are not typical for pneumonia, the patient is not included in the clinical trial. The investigator determines a therapeutic approach in compliance with the current standards.

At the first visit (day 1), patients are randomized to one of two treatment groups: patients in Group 1 receive Amoxicillin + Clavulanic acid (Amoxiclav) and Rafamine for 7 days; patients in Group 2 take Amoxiclav and Placebo for 7 days. All patients are provided with the drug Amoxiclav. In addition, all patients are provided with the antipyretic drug Paracetamol and a classic mercury-free thermometer to measure axillary temperature.

A second visit (3/4 days) is carried out 48-72 hours after the start of treatment to assess the effectiveness and safety of the initial course of antibiotic therapy. The investigator collects complaints, performs physical examination, and evaluates the vital signs and SpO2 level. If there is no response to initial antibiotic therapy, the decision about the therapeutic approach is made by the investigator. If hospitalization occurs, the patient ends participation in the study because he or she has reached the study endpoint.

If antibiotic therapy is effective, it is continued for 7 days. After 7 days of treatment, a third visit is carried out (day 8), at which the researcher collects the patient's complaints, conducts a physical examination and assessment of vital signs, measures SpO2 and prescribes a clinical blood test. If the patient meets the criteria for sufficiency of antibiotic therapy, the investigator stops prescribing the antibiotic.

If a positive response to the first course of antibiotic therapy is achieved, the patient continues to participate in the study. The patient is observed for 7 days. On day 15±1, the fourth visit is carried out, during which the researcher collects the patient's complaints, conducts a physical examination and assesses vital signs, measures SpO2 and prescribes a follow-up X-ray/CT scan. The patient returns the study drug and the investigator performs a compliance calculation. In total, patients are observed for 15 days.

The study uses an electronic patient diary (EPD) to record axillary temperature daily in the morning and evening. All temperature measurements during the study should be made with the same thermometer. The patient should bring the thermometer used for measurements to the health center visit. In addition, the patient should also use the EPD to record symptoms, if any, time of administration of the antipyretic dose, and any worsening of his/her condition (if applicable) to assess safety and record adverse events.

The investigator teaches the patient how to complete the diary at Visit 1. The EPD is available for completion throughout the patient's participation in the study.

An unscheduled visit may be made during the study if the patient's condition worsens or at the discretion of the investigator.

If clinical cure is not achieved by 15±1 days, the patient ends participation in the study because he or she has reached the study endpoint. The researcher determines the approach to further observation and treatment of the patient in accordance with current recommendations.

Subjects are permitted to take medications for concomitant medical conditions during the study, with the exception of medications listed in the Prohibited Concomitant Treatments section.

03

Conditions studied

  • Community-acquired Pneumonia
  • Pneumonia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged 18-65 years.
  2. The diagnosis of community-acquired pneumonia presupposes that the patient has focal infiltration of the lung tissue, confirmed by imaging (X-ray/CT), and the presence of at least two clinical symptoms:

    а) acute fever at the onset of the disease (axillary temperature ≥ 38.0°C); b) wet cough; c) physical signs (crepitus/wheezing, bronchial breathing sounds, local dullness to percussion); d) leukocytosis >10×10\^9/L and/or shift of band neutrophils (>10%).

  3. SpO2 ≥95% according to pulse oximetry.
  4. Overall CRB-65 score "0" points.
  5. Patients willing to use reliable methods of during the study (men and women of ).
  6. Patients who have signed the patient information sheet and .

Exclusion criteria

Exclusion Criteria:

  1. Any indications for patient hospitalization.
  2. Suspected infiltrative pulmonary tuberculosis.
  3. Medical history of/suspected malignant neoplasm of any location, including primary lung cancer and to the lung parenchyma.
  4. Suspected pulmonary embolism and pulmonary infarction.
  5. Medical history of , bronchial asthma, chronic respiratory failure.
  6. Medical history of immune system diseases: systemic vasculitis, lupus pneumonitis, allergic bronchopulmonary aspergillosis, obliterating bronchiolitis, idiopathic pulmonary fibrosis, eosinophilic pneumonia, bronchocentric granulomatosis.
  7. Chronic heart failure III or IV FC (according to the classification, 1964).
  8. Suspicion of drug-induced (toxic) pneumopathy, aspiration of foreign body, sarcoidosis, pulmonary alveolar proteinosis, lipoid pneumonia, rounded atelectasis.
  9. Exacerbated or decompensated chronic diseases, including diabetes mellitus, affecting a patient's ability to participate in the clinical trial.
  10. Prior diagnosis of immunodeficiency of any etiology.
  11. Patients having unstable angina pectoris or myocardial infarction in the previous 6 months.
  12. Prior history of chronic kidney disease (categories С3-5 А3).
  13. Prior history of hepatic failure ( class C).
  14. Any surgery within the previous 3 months.
  15. Patients who received any medicine specified in the section "Prohibited concomitant treatment" within 3 months preceding the inclusion in this study or who require the use of medicines that are prohibited within this trial.
  16. Malabsorption syndrome, including congenital or acquired lactase deficiency (or any other disaccharidase deficiency) and galactosemia.
  17. to any of the components of medications used in the treatment.
  18. Pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use methods during the trial.
  19. Patients who, from the investigator's point of view, will not comply with study monitoring requirements or with study drug administration requirements.
  20. Prior history of a psychiatric disorder, alcoholism or drug abuse, which in the opinion of the investigator may compromise compliance with the study protocol.
  21. Participation in other clinical studies within 3 month prior to enrollment in the study.
  22. Patients who are related to any of the on-site research personnel directly involved in the conduct of the trial or are an immediate relative of the study investigator. 'Immediate relative' means husband, wife, parents, children, or siblings, regardless of whether they are natural or adopted.
  23. Patients who work for OOO "NPF "MATERIA MEDICA HOLDING" (i.e. the company's employees, temporary contract employees, persons designated officials responsible for carrying out the research or any immediate relatives of the aforementioned).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
370 participants (actual)

Study arms

  • Experimental
    Raphamin

    Oral administration, without food. The tablet should be held in the mouth until complete dissolution. On the first day 8 tablets are administered using the following scheme: 1 tablet every 30 minutes in the first 2 hours (5 tablets in total within 2 hours), followed by three more tablets at regular intervals during the rest of the day. From day 2 onwards, 1 tablet taken 3 times daily. The treatment period is 7 days.

    Drug: Raphamin

  • Placebo comparator
    Placebo

    Oral administration, without food. The tablet should be held in the mouth until complete dissolution. Placebo is administered according to the Raphamin regimen for 7 days.

    Drug: Placebo

Interventions

  • Tablet for oral use.

    Also known as: MMH-407

  • DrugPlacebo

    Tablet for oral use.

06

What researchers measure

Primary outcomes

  1. Percentage of patients with clinical cure at the test of cure (TOC) visit

    Percentage of patients with clinical cure at the TOC visit (on day 8 after randomization based on the physician's assessment of clinical symptoms).

    Time frame: On 8 days

Secondary outcomes

  1. Average duration of antibacterial therapy

    Average duration of antibacterial therapy in two groups

    Time frame: 15 days

Other outcomes

  1. Proportions of patients with a positive response to the initial course of antibiotic therapy after 48-72 hours

    Proportion of patients with a positive response to the initial course of antibiotic therapy after 48-72 hours in two groups. The main criteria for the effectiveness of the starting regimen of antibacterial therapy after 48-72 hours: a decrease in temperature (below 38.0C), a decrease in the severity of intoxication syndrome and the main clinical symptoms of pneumonia, primarily shortness of breath.

    Time frame: 3 days

  2. Proportion of patients who discontinue antibiotic therapy after 7 days of treatment (based on physician assessment of clinical symptoms).

    Proportions of patients who discontinue antibiotic therapy after 7 days of treatment in two groups (based on physician assessment of clinical symptoms). Criteria for the sufficiency of antibacterial therapy (all of the following must be present): * persistent decrease in body temperature ≤37.2ºС for at least 48 hours; * absence of intoxication syndrome; * respiratory rate \<20/min (in patients without chronic respiratory failure); * absence of purulent sputum (except for patients with its constant secretion); * the number of leukocytes in the blood \<10×109/l, neutrophils \<80%, young forms \<6%.

    Time frame: 7 days

  3. Proportion of patients who required a change in antibiotic 48-72 hours after initiation of therapy.

    Proportions of patients who required a change in antibiotic 48-72 hours after initiation of therapy in two groups due to treatment failure. The main criteria for the treatment failure: temperature higher than 38.0C), presence of intoxication syndrome and the main clinical symptoms of pneumonia, shortness of breath.

    Time frame: 3 days

  4. Time until a persistent decrease in body temperature ≤37.2ºС (according to the patient's diary).

    Time until a persistent decrease in body temperature ≤37.2ºС (according to the patient's diary) in two groups.

    Time frame: 15 days

  5. Proportion of patients who required a second course of antibiotic therapy.

    Proportions of patients who required a second course of antibiotic therapy in two groups due to treatment failure. The main criteria for the treatment failure: temperature higher than 38.0C), presence of intoxication syndrome and the main clinical symptoms of pneumonia, shortness of breath.

    Time frame: 15 days

  6. Proportion of patients who required hospitalization during 15 days of follow-up.

    Proportions of patients who required hospitalization during 15 days of follow-up due to treatment failure. The main criteria for the treatment failure: temperature higher than 38.0C), presence of intoxication syndrome and the main clinical symptoms of pneumonia, shortness of breath.

    Time frame: 15 days

  7. Number of antipyretic drug doses taken during 7 days of the initial course of antibacterial therapy (per patient).

    Average number of antipyretic drug doses taken during 7 days of the initial course of antibacterial therapy (per patient) in two groups according to the patient's diary.

    Time frame: 7 days

  8. Proportion of patients without infiltration on x-ray/CT 14 days after randomization.

    Proportions of patients without infiltration on X-ray/CT on 14th day after randomization in two groups according to medical records.

    Time frame: 14 days

  9. The Presence of Adverse Events (AEs).

    The presence and nature of adverse events, their intensity (severity), causal relationship to the study drug, outcome. Based on medical records.

    Time frame: 15 days

  10. Changes in Vital Signs (Blood Pressure measured in mm Hg)

    Changes in Blood Pressure at the end of treatment. Based on medical records.

    Time frame: 15 days

  11. Changes in Vital Signs (Pulse Rate (Heart Rate) measured in beats per minute)

    Changes in Heart Rate at the end of treatment. Based on medical records.

    Time frame: 15 days

  12. Changes in Vital Signs (Respiratory Rate (Breathing Rate) measured in breaths per minute)

    Changes in Respiratory Rate at the end of treatment. Based on medical records.

    Time frame: 15 days

07

Study locations

38 sites
  • Aramil city hospital
    Aramil, 624002, Russian Federation
  • Northern Medical Clinical Center named after N.A. Semashko Federal Medical and Biological Agency
    Arkhangelsk, 163000, Russian Federation
  • Gatchina Clinical Interdistrict Hospital
    Gatchina, 188300, Russian Federation
  • Ivanovo Clinical Hospital named after Kuvayevs
    Ivanovo, 153025, Russian Federation
  • City Clinical Hospital # 9 of the Ministry of Health of the Udmurt Republic
    Izhevsk, 426063, Russian Federation
  • Central City Clinical Hospital
    Kaliningrad, 236005, Russian Federation
  • Kazan State Medical University/Department of Infectious Diseases
    Kazan, 420012, Russian Federation
  • Kazan State Medical University
    Kazan, 420012, Russian Federation
  • Kuban State Medical University/Department of Infectious Diseases and Phthisiopulmonology
    Krasnodar, 350063, Russian Federation
  • Central Research Institute of Epidemiology
    Moscow, 111123, Russian Federation
  • First Moscow State Medical University named after I.M. Sechenov
    Moscow, 119991, Russian Federation
  • Moscow Regional Research Clinical Institute named after. M.F. Vladimirsky
    Moscow, 129110, Russian Federation
  • Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko
    Nizhny Novgorod, 603093, Russian Federation
  • LLC "Persona group of companies"
    Nizhny Novgorod, 603155, Russian Federation
  • Clinical Hospital # 4
    Penza, 440067, Russian Federation
  • LLC "Professor's clinic"
    Perm, 614070, Russian Federation
  • Nikolaevskaya hospital
    Petergof, 198510, Russian Federation
  • LLC "4D Ultrasound Clinic"
    Pyatigorsk, 357502, Russian Federation
  • Rostov Central District Hospital
    Rostov, 152155, Russian Federation
  • St. Petersburg Research Institute of Phthisiopulmonology
    Saint Petersburg, 191036, Russian Federation
  • LLC "Energy of Health"
    Saint Petersburg, 194156, Russian Federation
  • LLC "Medical center "Reavita Med SPb"
    Saint Petersburg, 194354, Russian Federation
  • LLC "Medical Clinic"
    Saint Petersburg, 194356, Russian Federation
  • City Polyclinic # 112
    Saint Petersburg, 195427, Russian Federation
  • LLC "Zvezdnaya Clinic"
    Saint Petersburg, 196158, Russian Federation
  • City Pokrovskaya Hospital
    Saint Petersburg, 199106, Russian Federation
  • City Polyclinic # 4
    Saint Petersburg, 199178, Russian Federation
  • LLC "Meili"
    Saint Petersburg, 199406, Russian Federation
  • Medical University "Reaviz"
    Samara, 443001, Russian Federation
  • Samara State Medical University/Department of General and Clinical Microbiology, Immunology and Allergology
    Samara, 443099, Russian Federation
  • Smolensk State Medical University
    Smolensk, 214019, Russian Federation
  • LLC "Scientific Medical Center of General Therapy and Pharmacology"
    Stavropol, 355000, Russian Federation
  • Bashkir State Medical University/Department of Internal Medicine
    Ufa, 450008, Russian Federation
  • Ulyanovsk Regional Clinical Hospital
    Ulyanovsk, 432017, Russian Federation
  • Regional Clinic Hospital
    Vladimir, 600023, Russian Federation
  • Voronezh Regional Clinical Hospital # 1
    Voronezh, 394066, Russian Federation
  • Clinical Hospital # 2
    Yaroslavl, 150030, Russian Federation
  • LLC "Medical Center for Diagnostics and Prevention Plus"
    Yaroslavl, 150040, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Mar 2025, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2024
First posted
Feb 16, 2024
StartActual
Dec 1, 2023
Primary completionActual
Mar 19, 2025
CompletionActual
Mar 19, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06263881
Responsible party
Sponsor
First posted
Feb 16, 2024
Start date
Dec 1, 2023
Primary completion
Mar 19, 2025
Completion
Mar 19, 2025
Last update
Apr 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MMH-407

Start the discussion